ABIOMED, Inc. (ABMD)
(Delayed Data from NSDQ)
$271.75 USD
+6.98 (2.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $271.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$271.75 USD
+6.98 (2.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $271.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Headquartered in Danvers, MA and founded in 1981, ABIOMED Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. Abiomed’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.
ISRG or ITGR: Which is a Better Medical Instrument Stock?
by Zacks Equity Research
Intuitive Surgical (ISRG) and Integer Holdings' (ITGR) strong fundamentals and rising share price make them close contenders.
Here's Why You Should Steer Clear of Express Scripts for Now
by Zacks Equity Research
Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.
Cardinal Health (CAH), CD&R to Jointly Invest in naviHealth
by Zacks Equity Research
Cardinal Health (CAH) intends to boost its acute-care program platform by jointly investing in the earlier acquired naviHealth along with Clayton, Dubilier & Rice.
Here's Why You Should Sell Patterson Companies Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, unfavorable price movements, declining dental revenues and integration risks pose significant challenges for Patterson Companies (PDCO).
Wright Medical Gets FDA PMA for AUGMENT Injectable, Shares Up
by Zacks Equity Research
Wright Medical's (WMGI) AUGMENT Injectable Bone Graft platform has same clinical indications as the company's flagship AUGMENT Bone Graft.
Top Ranked Momentum Stocks to Buy for June 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 15th:
PetMed (PETS) Optimistic About New Orders Amid Cost Woes
by Zacks Equity Research
The whole of fiscal 2018 demonstrates an upbeat momentum for PetMed's (PETS) new order sales, primarily backed by aggressive advertising.
Medtronic ActivaProgramming Application Wins FDA Nod for DBS
by Zacks Equity Research
Medtronic's (MDT) ActivaProgramming Application is designed for use with Samsung Galaxy Tab S2 tablets. The therapy incorporates the inputs of more than a 100 clinicians worldwide.
3 Medical Instrument Stocks to Gain on Solid Market Prospects
by Zacks Equity Research
Here we take a peek at three Medical Instrument stocks that are likely to deliver strong returns in the days to come.
Cardinal Health to Gain From FDA Panel Vote for INCRAFT PMA
by Zacks Equity Research
Cardinal Health's (CAH) INCRAFT receives favorable recommendation from FDA for premarket approval.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical's (VAR) solid product portfolio and strong global foothold make it a lucrative pick.
Medidata Solutions (MDSO) Rallies 10.4% on Solid Q1 Earnings
by Zacks Equity Research
Medidata Solutions (MDSO) reports strong Q1 earnings and solid growth across segments.
Pacific Biosciences to Gain From New Genome Sequencing Tools
by Zacks Equity Research
Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.
Is ABIOMED (ABMD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is ABIOMED, Inc. (ABMD) Outperforming Other Medical Stocks This Year?
Why You Should Add IDEXX (IDXX) Stock to Your Portfolio?
by Zacks Equity Research
IDEXX's (IDXX) stellar performance is primarily driven by robust sales at the CAG (Companion Animal Group) business.
ABMD or VAR: Which is a Better Medical Instrument Stock?
by Zacks Equity Research
It is pretty difficult for investors to choose from MedTech bigwigs Abiomed (ABMD) and Varian Medical (VAR) as both the companies are riding on solid estimate revision and other developments.
Varian to Demonstrate Brachytherapy Solutions Portfolio
by Zacks Equity Research
Varian (VAR) will demonstrate four brachytherapy solutions in the American Brachytherapy Society Annual Meeting in San Francisco.
Becton, Dickinson Ties Up With Helmer Scientific to Boost MMS
by Zacks Equity Research
Becton, Dickinson (BDX) aims to boost its MMS segment through the promotion of its Pyxis ES refrigerator.
Here's Why You Should Sell Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) faces sluggishness in the exam-gloves unit lately. Further, cutthroat competition in the niche space is a headwind.
Here's Why You Should Buy Abiomed (ABMD) Stock Right Now
by Zacks Equity Research
Abiomed's (ABMD) solid Impella product line and the inclusion in the S&P 500 connect make it a lucrative pick.
Here's Why You Should Invest in Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker's (SYK) focus on inorganic expansion and stellar Mako performance make the stock an attractive buy.
Here's Why You Should Sell Accuray (ARAY) Stock Right Now
by Zacks Equity Research
Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).
Express Scripts' Inside Rx to Cut Medical Costs for the Aged
by Zacks Equity Research
Express Scripts (ESRX) keeps its commitment towards patient benefit management through subsidiary Inside Rx.
McKesson (MCK) Acquires Medical Specialties for $800 million
by Zacks Equity Research
McKesson's (MCK) solid acquisition portfolio is likely to benefit the company over the long haul.
Why Is ABIOMED (ABMD) Up 13.6% Since Its Last Earnings Report?
by Zacks Equity Research
ABIOMED (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.